Blood products and vaccines supplier CSL has reported a six per cent fall in annual profit and is tipping a slightly better earnings performance in 2022/23.
Blood products and vaccines supplier CSL has reported a six per cent fall in annual profit and is tipping a slightly better earnings performance in 2022/23.